PMLS 2019 WEST2019-08-16T15:21:38+00:00

Building on the successes of our events in Philadelphia and Jersey City, we are excited to be back where it all began – San Diego.  Please join us for the most thought-provoking Precision Medicine event in the marketplace. Our speakers cover the panoply of leaders in the healthcare continuum, these include clinicians, industry experts, academics, regulators, payers, genetic counselors, bioinformaticians, and many more who are shaping the way Precision Medicine is implemented into healthcare systems on a global scale.

Join us for panel discussions, keynotes, “Meet the Expert”, roundtables, networking, exhibits, and opening reception to hear from thought leaders who are making the promise of Precision Medicine a reality.



Bristol-Myers Squibb


Thermo Fisher Scientific


Visual Strata
Genome Medical
University of Arizona




Registration & Breakfast Buffet


Welcome and Opening Remarks

Dawn Barry, MBA, President & Co-Founder, LunaDNA – Chair – The Precision Medicine Leaders Summit – West

Nigel Russell, Founder & President, The Journal of Precision Medicine and the Precision Medicine Leaders Summits.


Keynote – Precision Medicine: Complexity Beyond Simple Mutations

John Quackenbush, PhD, Henry Pickering Walcott Professor of Computational Biology and Bioinformatics, Chair, Department of Biostatistics, TH Chan School of Public Health, Harvard University

Early successes in precision medicine were driven by identifying, and targeting, single genetic variants exhibiting large biological effects. However, we are increasingly coming to recognize that disease phenotypes, including response to targeted therapies, involve a much more complex landscape of genetic and other factors. Embracing this complexity, and developing new predictive methods, is necessary if we are to make continued advances and extend effective predictive medicine beyond oncology.


Panel – TBD


Opportunities to Advance Precision Medicine with Blockchain Powered AI

David Houlding MSc CISSP CIPP, Principal Healthcare Lead, Industry Experiences, Cloud + AI, Microsoft Corporation

AI is the powerhouse translating the growing tsunami of healthcare data near real-time into actionable insights, empowering healthcare professionals to improve patient outcomes, reduce healthcare costs, and even improve patient engagement and experiences. However, AI and ML are data hungry, and good models with low error rates, which are paramount in healthcare where patient lives are at stake, require hundreds of thousands if not millions of high quality patient data records to train precision medicine models from. Exacerbating this challenge is the fact that, while the required volumes of data do exist across the healthcare industry, data is mostly isolated across silos within healthcare organizations with little or no sharing, and as a result most AI initiatives draw data from just a single organization or silo with limited success, stunting the potential of AI in precision medicine. What if where was a way for a consortium of healthcare organizations to collaborate on AI for precision medicine, rather than each organization “going it alone”? Blockchain is designed to enable secure collaboration and sharing of data across a consortium. In this session we discuss opportunities for blockchain to enable collaboration and sharing across a consortium of healthcare organizations, of training data, provenance information, models, results, validation of results, audit trails and more to power AI to the next level in precision medicine.


Coffee & Meet the Expert


Precision Medicine in Complex Disease: Leveraging Polygenic Models to Define Genetic Risk and Stratification Towards Improving Prevention, Diagnosis, and Effective Treatment

Moderator:    Christina Waters, PhD, MBA, President, CEO and Founder RARE Science, Inc

Panelists:     Julie Collens, PhD, CEO & Founder, Vivid Genomics, Jessica Gibson CEO, Ariel Precision Medicine


The Health Economics of Companion Diagnostics and Laboratory Developed Tests

Moderator: Lori Anderson, XIFIN, Inc.

Panelists: Gabriel A. Bien-Willner, MD, PhD, FCAP, Medical Director, MolDX, Chief Medical Officer, Palmetto GBA, Trish Brown, Director; AMR Payer Partner and Field Market Access Lead, Illumina, Bruce Quinn MD PhD, Principal
Bruce Quinn Associates LLC,  Rina Wolf, VP Commercialization Strategies, Consulting and Industry Affairs





Population-scale Human Genetics and Genomics for NASH Drug Target & Biomarker Discovery

Richard Williams, MBBS PhD, Managing Director, Head of Oncology Programs at WuXi NextCODE

New drug targets & biomarkers are desperately needed for precision NASH therapy, monitoring & prevention.

In our global NASH discovery programs, we are (1) using whole genome sequencing (WGS) to compare thousands of patients with high fibrosis NASH, Low or No fibrosis NASH & NAFL, and population controls, and (2) interrogating hundreds of fresh liver biopsies from NASH & NAFL patients and control individuals with ‘bulk’ multi-omic genomic analysis (WGS, RNA-Seq, DNA methylation), single cell RNA-seq and fully-integrated AI to reveal novel disease biology, drug targets and biomarkers and enable precision medicine for liver disease.


Redefining The Role  for the Precision Medicine Clinical Laboratory

Moderator: Steven M Anderson, PhD, Chief Scientific Officer – Covance, Sr VP LabCorp


Coffee & Networking


Precision 20 –

Brian Meyer, PhD, Chairman, Department of Genetics Research Centre, KFSH&RC


Alternative Non-Mutation Based Approach to the Early Detection of Cancer

Moderator: Nic Dracopoli, PhD, Consultant


A Cancer Patient’s Perspective on Clinical Drug Trials

Laura Holmes Haddad, Best Selling Author & Patient Advocate

Drug investigators depend on them; oncologists turn to them when there are no other options; and patients fear them: this is the clinical trial in the U.S. healthcare system. But among the myriad players in this critical aspect of precision medicine, there is little understanding of what actually happens once the patient has enrolled.
Join me as I share my experience as a 37 year old, StIV inflammatory breast cancer patient in a Phase 1 extension trial. I’ll be discussing important details about patient life in a trial, including traveling by plane to access a trial; arranging childcare support for our two young children; and the complicated route to accessing the trial itself.
By sharing the highs and lows, and the financial and emotional toll of the trial experience itself, I hope to help move the needle for patients in clinical trials. This includes improving patient education and access to trials among cancer patients.


Networking Reception at The Alexandria – enjoy drinks and hors d’houvres with fellow attendees, speakers and sponsors.



Breakfast Buffet


Women on Board of Directors Make Precision Medicine Companies Better

Co-Moderators: Tara Kochis-Stach, President, Slone Partners and Coco Brown, Founder,  Athena Alliance

Panelists: Chris Cournoyer, MA, Consultant, Dawn Barry, MBA, President & Co-Founder LunaPBC, Mary Stutts, MHA,  Chief Diversity, Inclusion & Health Equity Officer, Stanford Health Care, Gail Marcus, MBA, PhD, Professor, Massachusetts College of Pharmacy and Health Sciences.

An abundance of international evidence concludes that women propel organizations to outperform the competition. Presented and co-moderated by Slone Partners President Tara Kochis-Stach and Athena Alliance Founder Coco Brown, Women on Boards of Directors Make Precision Medicine Companies Better examines the benefits that gender diversity plays in organizational performance. Over 90 minutes, exceptional panelists who possess uncommon expertise in scientific healthcare executive management, finance, law, corporate governance, marketing, and ethics explore how precision medicine company boards populated by greater numbers of women can reap unique rewards.


Accelerating Preventive Genomics: Risks, Rewards and Reality

Robert C. Green, MD, MPH, Associate Physician, Brigham and Women’s Hospital, Professor of Medicine, Harvard Medical School, Geneticist, Brigham and Women’s Hospital, Director, Genomes2People Research Program


Coffee & Meet The Expert


Evolution of CAR-T Cell Therapy: Hype, Progress and Challenges

Moderator:      Alessandra Cesano, MD, Chief Medical Officer, Essa Pharma

Panelists:          Adrian Bot, MD, PhD., Vice President, Translational Medicine, Kite, a Gilead Company

Chimeric antigen receptor (CAR) T cell therapy has shown to provide long lasting remission in a subset of patients with certain hematologic malignancies for whom chemotherapy had failed. With 2 FDA approved products commercially available for licensed indications in ALL and DLBCL, there is a fast-growing business in delivering CAR-T cells. While researchers, physicians, patients, and investors alike are seduced by such potential, there are still several major hurdles to overcome. Specifically, for the vast majority of patients with blood cancer, and all with solid cancers, CAR-T cells are not yet proven to be effective, are too toxic, or are not available due to expense or geography. This panel will focus on where the field is right now, and consider the issues that must be addressed as the field moves forward, in order to fulfill the promise of recent successes.


Moving Precision Medicine from Rhetoric to Reality

Roy Smythe, M.D, CEO, SomaLogic, Inc.


Keynote – Implementing Precision Medicine for Pediatric Oncology

Tim Triche, MD, PhD,  Co-Director for the Children’s Hospital Los Angeles (CHLA) Center for Personalized Medicine




Standardizing Cancer Immunotherapy Diagnostic Assays: The Medical Imperative, the Challenges, and a Roadmap to Optimizing Delivery of Precision Medicine

Steven Averbuch, MD, Principal, S D Averbuch Consulting LLC


Education in Precision Medicine


Networking Break


Lessons Learned from 20 Years in Precision Medicine

Kristine Ashcraft – CEO, YouScript

This talk will examine the successes and stumbling blocks experienced in two decades of bringing precision medicine and pharmacogenomics to clinical care. I will present several key lessons and how to apply them to the current state of the industry and look at current opportunities ripe for disruption and positive change. From optimizing communication and outreach to providers and patients, to proving value to various stakeholders, to the importance of establishing success metrics we’ll take a look backwards so we can move the innovation flywheel faster in the next 20 years.


Panel – TBD


Closing Remarks


Lori Anderson

Lori Anderson

Product Marketing Manager, XIFIN, Inc.

Lori Anderson is product marketing manager for precision medicine informatics at XIFIN, where she brings many years of experience in medical affairs and product portfolio management in the healthcare and life-sciences industries. Prior to joining XIFIN, Lori was the director of health economics and outcomes research at Quest Diagnostics where she defined the reimbursement strategy for numerous tests routinely used in precision medicine. As a laboratorian herself with a particular interest in hematological neoplasms and the role of platelets in cardiovascular disease, Lori has contributed to the publication of 10 book chapters, 20 peer reviewed publications and over 40 poster presentations and has presented on numerous topics in laboratory medicine and life sciences worldwide.

Hannah Mamuszka

Kristine Ashcraft, MBA

CEO & Founder, YouScript

Kristine Ashcraft, B.S., MBA is a molecular biologist by training and is CEO and founder of YouScript. She has worked in the precision medicine space since 2000 and was recently named one of the 25 leading voices in precision medicine. Kristine has authored multiple publications on the clinical and economic benefits of pharmacogenomic testing including one lauded as one of the most influential publications at an AMIA meeting. She has been interviewed by numerous media outlets including the New York Times, the Wall Street Journal, and NBC Nightly News and has spoken at SXSW, ASHG, and numerous precision medicine Conferences. She is committed to being a catalyst in the adoption of precision medicine.

Hannah Mamuszka

Dawn Barry, MBA

President & Co-Founder, LunaPBC

Dawn Barry is the President and Co-Founder of public benefit corporation, LunaPBC, which launched, LunaDNA, in December 2018 following SEC-qualification. LunaDNA is a community-owned health data sharing platform where individuals are included in the value created through its data for ownership shares model.  Prior to LunaDNA, Dawn served as the Vice President of Applied Genomics at Illumina, Inc.  Dawn joined Illumina in 2005 as their first Market Development Specialist and grew to hold leadership roles in business units, sales, and marketing for the Company. Dawn was named San Diego Business Journal’s 2017 Business Woman of the Year, was a speaker at TEDxSanDiego 2016, and is a Board Chair of the Alzheimer’s Association San Diego/Imperial Chapter. She holds a BS in Biology from the University of Vermont and a MBA from the University of Connecticut School of Business.

Hannah Mamuszka

Coco Brown

Founder, CEO, COO, Board Director and Advisor, The Athena Alliance

Coco Brown leads change and transformation, accelerating multimillion-dollar growth through vision, strategy, technology, and people leadership.
Coco has held leadership roles including CEO, COO, President, board member, and advisor, partnering with F1000 companies, start-ups, and nonprofits, delivering successful outcomes for Apple, Cisco, eBay, Facebook, Silicon Valley Bank and many others. Currently, Ms. Brown is the Founder, CEO, and board member of The Athena Alliance a game-changing executive firm helping to position top 10% of executive women for advancement and board opportunities while also transforming the board room towards a modern composition model. Since founding Athena in the Spring of 2016,  Ms. Brown has led the organization to a network of over 1000 C-Level women, VCs, and CEOs from over 150 companies including Accenture, Cisco, Microsoft, Intuit, Autodesk, and Alphabet / Google. Within two years, Coco has overseen 20 board placements and secured $2 million in income through corporate and investor service offerings.

Hannah Mamuszka

Alessandra Cesano, MD, PhD

Chief Medical Officer, ESSA

Alessandra Cesano, MD, PhD has recently joined ESSA as Chief Medical Officer.

Previously she has been the Chief Medical Officer of NanoString Inc from July 2015 until June 2019 where she focused in the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response/resistance.

Prior to joining NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. and before then she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R and D group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals.

Early in her professional career Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania.

She also holds membership in several professional and scientific societies including ASCO, ESMO, ASH, EHA, AACR and SITC. In the latter she serves as co-chair in the SITC Industry Committee, Associate Editor for the Biomarker section of JITC and is an active member of the SITC Biomarker Working Group.
Over her careers she has been an author on over 100 publications.

Dr. Cesano received an MD summa cum laude, a Board Certification in Oncology and a PhD in Tumor Immunology from the University of Turin.

Chris Couryner

Chris Cournoyer, MA, MIT Executive Education Program

Strategic Advisor, Qiagen

Chris is an accomplished software executive who has a track record for successfully applying technology to create and transform businesses across industries including retail, healthcare IT and molecular diagnostics. Ms. Cournoyer has a broad range of strategic, technological, operational, financial and management experience in Software and Healthcare IT, with companies from $5m to $200b in annual revenue. Most recently, Chris served as the Chairperson for the Board of Directors for N-of-One, a privately held venture backed company in molecular diagnostics/genomics decision support. Chris has experience serving on the Finance, Audit, and Compensation Committees, and has chaired a Technology Committee for two of the boards and has also served on a nonprofit board as a member of the Emerson Hospital Board of Trustees. Leading teams with a focus on developing strategies for operational excellence, global partnerships, product direction and mergers and acquisitions, Chris has also successfully led the acquisition and integration of more than 15 companies. Ms. Cournoyer has strong functional knowledge of Information Technology, Healthcare, and Fulfillment Operations and has operated successfully in both large and small companies, publicly traded companies as well as privately venture backed companies. Chris has moved successfully across industries with software as the common thread across these companies. She has held executive general management roles in two publicly traded companies; was President and CEO in two venture backed companies and Vice President in two multi-billion companies.  Ms. Cournoyer has raised venture capital, planned, acquired and integrated over 15 acquisitions, and successfully sold two companies. Chris is presently a Strategic Advisor to Qiagen.

Hannah Mamuszka

Nicholas Dracopoli, PhD


Nicholas (Nic) Dracopoli, Ph.D. is currently a consultant to the biopharma and diagnostics . Prior to starting his consultancy, Nic was Senior Vice President of Translation Science at Personal Genome Diagnostics (PGDx) after eighteen years working in oncology drug development at Bristol Myers-Squibb (BMS) and Janssen Research & Development. In these roles, he was responsible for building two new translational science teams whose work contributed to the approval of six new oncology drugs for BMS and Janssen. Prior to joining the pharmaceutical industry, he spent five years in the biotechnology industry at Sequana Therapeutics. Nic obtained his bachelor’s degree and doctorate from the University of London and completed post-doctoral fellowships at the Memorial Sloan-Kettering Cancer Center in New York City and the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts. Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center and as a Section Chief at the National Center for Human Genome Research at the National Institutes of Health, Bethesda, Maryland. Nic has authored more than 70 scientific publications and has extensive experience in the fields of genomics, molecular biology and cancer research.

Hannah Mamuszka

Robert Green, MD, MPH

Associate Physician, Brigham and Women’s Hospital, Professor of Medicine, Harvard Medical School, Geneticist, Brigham and Women’s Hospital, Director, Genomes2People Research Program

Robert C. Green, MD, MPH, is a medical geneticist and physician-scientist who directs the G2P Research Program in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital and Harvard Medical School. Dr. Green is principal investigator of the MedSeq Project, the first NIH-funded randomized trial to explore the use of whole genome sequencing in the clinical practice of medicine.

Hannah Mamuszka

Laura Holmes Haddad

Best Selling Author & Patient Advocate

Laura Holmes Haddad is a writer and speaker from California. A former cookbook editor, Laura’s career focus shifted when she was diagnosed with Stage IV inflammatory breast cancer at the age of 37. After completing three years of treatment– including a Phase I extension clinical trial–she remains NED (no evidence of disease) and is committed to healthcare policy and patient advocacy work. Her speaking engagements have included the ACS Cancer Action Network,, Young Survival Coalition, and Blue Shield of California. She has also been a guest on numerous radio programs and podcasts.

In addition, Laura is the author of This is Cancer: Everything You Need to Know, from the Waiting Room to the Bedroom (Hachette, 2016). Follow her on Twitter (@HolmesHaddad) or at

Hannah Mamuszka

David Houlding, MSc, CISSP, CIPP

Principal Healthcare Lead, Microsoft

David Houlding is the Principal Healthcare Lead on the Microsoft Azure Industry Experiences Team. David has more than 24 years of experience in healthcare spanning provider, payer, pharmaceutical, and life sciences segments worldwide, and has deep experience and expertise in blockchain, cloud computing, privacy, security, compliance, and AI / ML. David currently serves as Chair of the HIMSS Blockchain in Healthcare Task Force, a group of ~100 leaders from across healthcare worldwide, collaborating to advance blockchain in healthcare. David also currently serves as an advisor to both the British Blockchain Association and Lifeboat Foundation. David has led the successful creation and deployment of a wide range of solutions to help reduce the cost of healthcare, improve patient outcomes, experiences, and engagement. Prior to joining Microsoft in 2018 David served for over 10 years at Intel Health & Life Sciences where he was the Director of Healthcare Privacy & Security, responsible for enabling healthcare organizations worldwide to achieve compliance with regulations and data protection laws, and implement effective privacy and security programs. In his current role at Microsoft, David works with key partners and industry influencers to enable healthcare organizations make use of cloud computing and related technologies to reduce healthcare costs, and enable new transformative healthcare use cases to improve patient outcomes, leveraging strategic technologies such as such as AI / ML, blockchain, IoMT (Internet of Medical Things), and others. David has a proven track record for innovation with 5 patents granted by the USPTO. David currently holds the CISSP (Certified Information Systems Security Professional), and CIPP (Certified Information Privacy Professional) credentials, and has a Master of Applied Science in Data Compression and Digital Signal Processing from Simon Fraser University, Canada.

Hannah Mamuszka

Tara Kochis-Stach

President, Slone Partners

Tara joined Slone Partners in 2004, bringing to the company over a decade of healthcare experience. Her successful sales career with industry leaders such as VERSYSS, American Medical Laboratories, and Quest Diagnostics covered a wide variety of healthcare segments, including information technology, medical records, and the diagnostic and laboratory testing industry.

Prior to healthcare, Tara recruited executive and management talent in the banking and finance sector. Tara’s executive abilities and business acumen have been instrumental in building Slone Partners into the successful and growing company it is today. Tara drives business development strategies, creating strong partnerships with new clients and strengthening relationships with existing clients. She is a tremendous resource for clients and prospects alike.

Through her partnership with Springboard Enterprises, she is an advisor to Blumio, a startup company focused on building sensors and systems to improve health and wellness, as well as a frequent panelist and speaker at industry conferences and a participant in select industry committees; activities that provide continuing opportunities to expand Slone Partners’ knowledge and expertise in the industries we serve.

Tara graduated cum laude from Boston College, receiving a Bachelor of Science with a concentration in Human Resources Management.

Hannah Mamuszka

Gail Marcus, MBA, MSE, PhD

Professor, Massachusetts College of Pharmacy & Health Sciences University

Ms. Marcus currently serves on two public company boards, Natera (NTRA) and Triple S (TSM) and two private company boards, Cambridge Epigentix and Binx Healthcare.  She is a highly experienced healthcare executive with both domestic (U.S.) and international leadership assignments.  She has worked in several healthcare sectors, including services, diagnostics, healthcare provision and managed care.  She brings an in-depth understanding of the complex U.S. healthcare reimbursement environment and strong financial and operational leadership experience.  Ms. Marcus has held leadership assignments in Fortune 100 healthcare companies, including United Healthcare and CIGNA,  as well as small, private equity backed diagnostic organizations.   She was named one of the top 100 women leaders in Massachusetts in 2014.  Ms. Marcus serves on the CMS advisory committee on diagnostic testing.    She has an academic appointment at Massachusetts College of Pharmacy and Health Sciences (MCPHS University), leading a cross section of programs in pharmaceutical business and administrative sciences.  Ms. Marcus holds a B.A. from Wesleyan University, a M.B.A in Accounting and Decision Sciences from the Wharton School, a M.S.E in computer science from the University of Pennsylvania and a doctorate in healthcare administration from the Medical University of South Carolina.  Ms. Marcus meets the requirements of a financial expert and achieved the Leadership Fellow designation from the National Association of Corporate Directors.

Hannah Mamuszka

Roy Smythe, MD

Chief Executive Officer, SomaLogic

Roy Smythe, M.D., joined SomaLogic in November 2018 as Chief Executive Officer. Originally trained as a thoracic surgeon and physician-scientist, Dr. Smythe subsequently gained highly diverse experience and expertise across many areas of cutting-edge healthcare, technology and translational medicine.

Dr. Smythe came to SomaLogic from Royal Philips, where he served as Chief Medical Officer for Strategy and Partnerships. Before joining Philips, he served as Chief Medical Officer at Valence Health, a Chicago-based healthcare company. He held the same title previously at AVIA, a healthcare technology accelerator.

Following medical school, he trained in surgery and completed a postdoctoral research fellowship in molecular therapeutics at the University of Pennsylvania. Dr. Smythe’s medical and research career then began at M.D. Anderson Cancer Center, and he subsequently chaired the Department of Surgery at Baylor Scott & White Health System and the Texas A&M Health Science Center College of Medicine where he was also Medical Director of Innovation before moving into expanded roles in healthcare delivery.

A highly sought-after lecturer and the author of more than 300 papers, abstracts and essays in academic, literary and humanities publications, Dr. Smythe is also currently a member in more than 20 U.S. national learned societies.

Hannah Mamuszka

Mary Stutts, MHA, Executive Program Graduate, Stanford University School of Business

Chief Diversity, Inclusion & Health Equity Officer at Stanford Healthcare

Ms. Stutts is the Chief Diversity, Inclusion & Health Equity Officer for Stanford Health Care.  In addition to a proven track record as a diversity, inclusion and health equity champion, Mary is an accomplished leader who thrives on living life to the fullest, never backing away from a challenge and not hesitating to embrace the new and unexplored. Mary’s energy and zest for maintaining a transformative mindset and helping others achieve life goals is contagious – making her a sought-after advisor, speaker, advocate and board member. She has provided global leadership in biotechnology, healthcare, technology and media industries at Fortune 200 companies including Genentech, Bayer, Bristol Myers Squibb, UnitedHealth Group and Comcast NBCUniversal as well as Kaiser Permanente. Her book, The Missing Mentor, Women Advising Women on Power, Progress & Priorities provides insight and guidance on career advancement with or without a mentor.  Her book and her career development workshops on the dynamics of women and men in leadership led to her receiving the Business Council for Peace 2019 Lifetime Impact Award for advancing the careers of women.

Mary is on the Board of the Global Women’s Funding Network – the largest philanthropic network in the world devoted to women and girls.  Ms. Stutts sits on Professional Advisory Boards for The NBA Wives Association, WorldWideWomen and Wellist.  Growing up as a foster child from the age of 5 and her passion for supporting, nurturing and developing girls, aspiring professionals and entrepreneurs led Stutts to found The Excellent Life Center (TCEL), a 501c3 organization. A graduate in Communications Management at the University of Louisiana, Mary earned a Master’s degree in Health Administration at the University of Southern California. Mary is also a graduate of the Executive Program on Strategy and Organization at the Stanford University Graduate School of Business.

Hannah Mamuszka

John Quackenbush, PhD

Henry Pickering Walcott Professor of Computational Biology and Bioinformatics
Chair, Department of Biostatistics, Harvard University T.H. Chan School of Public Health

John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard TH Chan School of Public Health and Professor of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute. John’s PhD was in Theoretical Physics, in 1992 he received a fellowship from the National Institutes of Health to work on the Human Genome Project, which led him from the Salk Institute to Stanford University to The Institute for Genomic Research (TIGR) before moving to Harvard in 2005. John’s research uses massive data from DNA sequencing and other assays to model functional networks in human cells. By comparing networks between groups of individuals, he has found new drug targets, explored chemotherapy resistance, and investigated differences between the sexes. He has made pioneering discoveries about how the genetic variants work together to determine our traits. John has published more than 280 papers; his work has been cited more than 65,000 times. He has received numerous awards for his work, including recognition in 2013 as a White House Open Science Champion of Change. He is also the co-founder of Genospace, a precision medicine software company that was purchased by the Hospital Corporation of America in 2017.

Hannah Mamuszka

Richard Williams, MBBS, PhD

Managing Director, Head of Oncology Programs , WuXiNextCODE

Dr. Richard Williams is Managing Director and Head of Oncology Programs at WuXiNextCODE.  He responsible for driving the science and commercialization of large oncology cohorts programs for gene and drug target discovery, and leads engagement with biopharma companies to drive utilization of cancer genomics to support their own clinical development programs.

Most recently, Dr. Williams served as Program Lead and Lead Medical Director for the Circulating Cell-Free Genome Atlas (CCGA) Program at GRAIL Inc. in Menlo Park, California. CCGA is the largest ever prospective survey of circulating nucleic acids in cancer and is key to the future development of blood-based early cancer detection products. Prior to serving at GRAIL, Dr. Williams held various oncology drug development positions, such as: Head of Amgen Early Development Oncology Group in the Medical Sciences Division at Amgen Inc., and Clinical Research Medical Director in the Hematology/Oncology Global Development Division, also at Amgen; as well as Senior Medical Director in the Clinical Research & Development Group at Puma Biotechnology Inc.

Dr. Williams received both his B.Med.Sc. (with Distinction) and his Ph.D. from the Department of Pathology at the University of Queensland, Australia. He received his Bachelor of Medicine, Bachelor of Surgery (with Honors) from the Faculty of Medicine at the University of Queensland, which is equivalent to an MD degree.


Myriad Women's Health




The Alexandria

10996 Torreyana Road
San Diego, CA 92121


There are numerous options for accommodation while attending the event. Please utilize your regular resources for travel and accommodation. The Precision Medicine Leaders’ Summit, Kneed Media, or The Alexandria do not engage with any third parties to provide assistance for accommodation or travel.

As you are probably aware there are numerous entities that may approach you to book your travel and accommodation, please ignore these solicitations as they are in no way associated with the Precision Medicine Leaders’ Summits.



Receive information about our 2019 conference speakers, schedule and registration.